Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

Next Previous
X
Search
Trial Profile

Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 113 (Primary)
  • Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HARE-40

    • Most Recent Events

    • 04 Nov 2024 According to a BioNTech media release, In September 2024, at ESMO, results were presented from an investigator-sponsored Phase 1/2 dose escalation clinical trial evaluating BNT113 alone in the post-adjuvant and metastatic settings in patients with HPV16+ head and neck and other cancers. BNT113 was shown to induce immune responses in patients in the adjuvant and end-stage clinical settings and to be overall well tolerated with a manageable safety profile.
    • 05 Aug 2024 According to a BioNTech media release, data from this study will be presented in at the 2024 Congress of the European Society of Medical Oncology taking place from September 13-17, 2024 in Barcelona, Spain.
    • 02 Feb 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top